Pyxis Oncology reports Q3 net loss of $22 mln

Reuters

Nov 03

<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> reports Q3 net loss of $22 mln

Overview

Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year
Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025
Expected cash runway through data milestones into second half of 2026

Outlook

Pyxis Oncology expects preliminary data from MICVO studies in 4Q25
Company anticipates cash runway into second half of 2026
Pyxis Oncology to announce next steps in MICVO development with data update

Result Drivers

G&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees
TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.35
Q3 Net Income		-$22 mln
Q3 Basic EPS		-$0.35
Q3 Income from Operations		-$23.46 mln

Press Release: ID:nGNX6XTnxk

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580290360"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580290360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580290360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580290360","market":"us","top_or_hot":-1,"title":"Pyxis Oncology reports Q3 net loss of $22 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> reports Q3 net loss of $22 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year</p></li><li><p>Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025</p></li><li><p>Expected cash runway through data milestones into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pyxis Oncology expects preliminary data from MICVO studies in 4Q25</p></li><li><p>Company anticipates cash runway into second half of 2026</p></li><li><p>Pyxis Oncology to announce next steps in MICVO development with data update</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>G&amp;A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees</p></li><li><p>TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$23.46 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6XTnxk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology reports Q3 net loss of $22 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology reports Q3 net loss of $22 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> reports Q3 net loss of $22 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year</p></li><li><p>Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025</p></li><li><p>Expected cash runway through data milestones into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pyxis Oncology expects preliminary data from MICVO studies in 4Q25</p></li><li><p>Company anticipates cash runway into second half of 2026</p></li><li><p>Pyxis Oncology to announce next steps in MICVO development with data update</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>G&amp;A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees</p></li><li><p>TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$23.46 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6XTnxk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL1N3WF0DM:1","article_id":"2580290360","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580290360","pubTimestamp":1762172153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pyxis Oncology reports Q3 net loss of $22 mlnOverviewPyxis Oncology reports Q3 net loss of $22 mln, consistent with prior yearCompany anticipates preliminary data from MICVO Phase 1 studies in Q4 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PYXS":"Pyxis Oncology, Inc."},"translate_title":"Pyxis Oncology报告第三季度净亏损2200万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":0.9},"content_text":"Pyxis Oncology reports Q3 net loss of $22 mlnOverviewPyxis Oncology reports Q3 net loss of $22 mln, consistent with prior yearCompany anticipates preliminary data from MICVO Phase 1 studies in Q4 2025Expected cash runway through data milestones into second half of 2026OutlookPyxis Oncology expects preliminary data from MICVO studies in 4Q25Company anticipates cash runway into second half of 2026Pyxis Oncology to announce next steps in MICVO development with data updateResult DriversG&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting feesTRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodelingKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.35Q3 Net Income-$22 mlnQ3 Basic EPS-$0.35Q3 Income from Operations-$23.46 mlnPress Release: ID:nGNX6XTnxkFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}